NPIL aims for "top three" services spot
Nicholas Piramal India Limited (NPIL), India's fourth largest pharmaceutical company, has launched its strategy to secure a "top three" spot in global custom services for its newly branded NPIL Pharma custom manufacturing business.
Nicholas Piramal India Limited (NPIL), India's fourth largest pharmaceutical company, has launched its strategy to secure a "top three" spot in global custom services for its newly branded NPIL Pharma custom manufacturing business.
It is planning a long-term strategic shift in the development and manufacture of APIs and intermediates by integrating flexible, cost-efficient formulation and manufacturing capability in India with acquired European and North American centres of excellence in early-phase technologies and production assets.
Having completed the acquisition of Avecia's pharmaceuticals business, including its Canadian subsidiary Torcan, in December 2005, NPIL sees acquisition as the key to continued growth for its custom manufacturing business. "Price and capacity issues have set the scene for a new phase in globalisation of the industry, where the real challenge is to offer the combined strengths of major players in India, Europe and North America on a fully integrated basis," said Dr R Ananthananarayanan, president of NPIL.
The company has four production sites in India; a GMP facility at Chennai; a commercial scale plant at Hyderabad and the four ex-Avecia/Torcan production facilities in Huddersfield, Grangemouth and Billingham in the UK and Aurora in Canada.
